Antibody-drug conjugates (ADCs) are increasingly important in oncology treatments. To accelerate their development, pharmaceutical companies are using a powerful combination of data-rich experimentation and mechanistic modeling to optimize processes from lab to manufacturing. This integrated approach is crucial for consistently maintaining Critical Quality Attributes (CQAs) and the Drug-to-Antibody Ratio (DAR) during scale-up. By applying kinetic and TFF modeling, along with simulation in crystallization and other unit operations, you can significantly reduce the experimental burden. This is especially critical for limiting operator exposure to the toxic materials often used in ADC processes. The methodologies highlighted in this poster help to create a robust and scalable process, while also ensuring product safety and quality. This ultimately leads to a faster and more efficient path to market for these life-saving drugs.
